Go Pro

Applied Therapeutics (APLT) Competitors

Applied Therapeutics logo
$0.10 0.00 (0.00%)
As of 06/29/2026

APLT vs. PMVP, OKYO, EXOZ, INKT, and XLO

Should you buy Applied Therapeutics stock or one of its competitors? MarketBeat compares Applied Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Applied Therapeutics include PMV Pharmaceuticals (PMVP), OKYO Pharma (OKYO), eXoZymes (EXOZ), MiNK Therapeutics (INKT), and Xilio Therapeutics (XLO). These companies are all part of the "pharmaceutical products" industry.

How does Applied Therapeutics compare to PMV Pharmaceuticals?

PMV Pharmaceuticals (NASDAQ:PMVP) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, media sentiment, dividends, analyst recommendations, profitability and earnings.

90.2% of PMV Pharmaceuticals shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 7.6% of PMV Pharmaceuticals shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

PMV Pharmaceuticals' return on equity of -68.98% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
PMV PharmaceuticalsN/A -68.98% -62.70%
Applied Therapeutics N/A -340.84%-175.00%

PMV Pharmaceuticals has a beta of 1.36, meaning that its stock price is 36% more volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

PMV Pharmaceuticals currently has a consensus target price of $5.00, suggesting a potential upside of 280.23%. Applied Therapeutics has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than PMV Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
PMV Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.67
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

PMV Pharmaceuticals has higher earnings, but lower revenue than Applied Therapeutics. Applied Therapeutics is trading at a lower price-to-earnings ratio than PMV Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
PMV PharmaceuticalsN/AN/A-$77.74M-$1.49N/A
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A

In the previous week, PMV Pharmaceuticals had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for PMV Pharmaceuticals and 0 mentions for Applied Therapeutics. PMV Pharmaceuticals' average media sentiment score of 0.96 beat Applied Therapeutics' score of 0.00 indicating that PMV Pharmaceuticals is being referred to more favorably in the media.

Company Overall Sentiment
PMV Pharmaceuticals Positive
Applied Therapeutics Neutral

Summary

PMV Pharmaceuticals beats Applied Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to OKYO Pharma?

Applied Therapeutics (NASDAQ:APLT) and OKYO Pharma (NASDAQ:OKYO) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, risk, institutional ownership, valuation and profitability.

Applied Therapeutics presently has a consensus price target of $1.00, indicating a potential upside of 870.87%. OKYO Pharma has a consensus price target of $6.33, indicating a potential upside of 325.06%. Given Applied Therapeutics' higher possible upside, equities research analysts clearly believe Applied Therapeutics is more favorable than OKYO Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
OKYO Pharma
1 Sell rating(s)
1 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.40

Applied Therapeutics has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, OKYO Pharma has a beta of 0.02, meaning that its share price is 98% less volatile than the broader market.

OKYO Pharma's return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
OKYO Pharma N/A N/A N/A

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 3.0% of OKYO Pharma shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 40.5% of OKYO Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, OKYO Pharma had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for OKYO Pharma and 0 mentions for Applied Therapeutics. OKYO Pharma's average media sentiment score of 0.45 beat Applied Therapeutics' score of 0.00 indicating that OKYO Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
OKYO Pharma Neutral

OKYO Pharma has lower revenue, but higher earnings than Applied Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
OKYO PharmaN/AN/A-$4.71MN/AN/A

Summary

OKYO Pharma beats Applied Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Applied Therapeutics compare to eXoZymes?

Applied Therapeutics (NASDAQ:APLT) and eXoZymes (NASDAQ:EXOZ) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, media sentiment, valuation, profitability, dividends and institutional ownership.

98.3% of Applied Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 72.4% of eXoZymes shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

eXoZymes has lower revenue, but higher earnings than Applied Therapeutics. eXoZymes is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
eXoZymes$70K1,001.00-$9.16M-$1.14N/A

Applied Therapeutics has a beta of 2.08, suggesting that its stock price is 108% more volatile than the broader market. Comparatively, eXoZymes has a beta of 2.66, suggesting that its stock price is 166% more volatile than the broader market.

Applied Therapeutics currently has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Applied Therapeutics is more favorable than eXoZymes.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
eXoZymes
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

eXoZymes' return on equity of -220.63% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
eXoZymes N/A -220.63%-141.26%

In the previous week, eXoZymes had 2 more articles in the media than Applied Therapeutics. MarketBeat recorded 2 mentions for eXoZymes and 0 mentions for Applied Therapeutics. eXoZymes' average media sentiment score of 1.19 beat Applied Therapeutics' score of 0.00 indicating that eXoZymes is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
eXoZymes Positive

Summary

eXoZymes beats Applied Therapeutics on 8 of the 14 factors compared between the two stocks.

How does Applied Therapeutics compare to MiNK Therapeutics?

MiNK Therapeutics (NASDAQ:INKT) and Applied Therapeutics (NASDAQ:APLT) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation, institutional ownership and media sentiment.

MiNK Therapeutics has a beta of 0.47, indicating that its stock price is 53% less volatile than the broader market. Comparatively, Applied Therapeutics has a beta of 2.08, indicating that its stock price is 108% more volatile than the broader market.

MiNK Therapeutics has higher earnings, but lower revenue than Applied Therapeutics. MiNK Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiNK TherapeuticsN/AN/A-$12.49M-$2.84N/A
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A

2.9% of MiNK Therapeutics shares are held by institutional investors. Comparatively, 98.3% of Applied Therapeutics shares are held by institutional investors. 20.4% of MiNK Therapeutics shares are held by company insiders. Comparatively, 1.6% of Applied Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

MiNK Therapeutics currently has a consensus target price of $35.00, indicating a potential upside of 194.61%. Applied Therapeutics has a consensus target price of $1.00, indicating a potential upside of 870.87%. Given Applied Therapeutics' higher possible upside, analysts plainly believe Applied Therapeutics is more favorable than MiNK Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiNK Therapeutics
1 Sell rating(s)
2 Hold rating(s)
1 Buy rating(s)
1 Strong Buy rating(s)
2.40
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67

MiNK Therapeutics' return on equity of 0.00% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
MiNK TherapeuticsN/A N/A -118.57%
Applied Therapeutics N/A -340.84%-175.00%

In the previous week, MiNK Therapeutics had 1 more articles in the media than Applied Therapeutics. MarketBeat recorded 1 mentions for MiNK Therapeutics and 0 mentions for Applied Therapeutics. MiNK Therapeutics' average media sentiment score of 1.89 beat Applied Therapeutics' score of 0.00 indicating that MiNK Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
MiNK Therapeutics Very Positive
Applied Therapeutics Neutral

Summary

MiNK Therapeutics beats Applied Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Applied Therapeutics compare to Xilio Therapeutics?

Applied Therapeutics (NASDAQ:APLT) and Xilio Therapeutics (NASDAQ:XLO) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings.

Applied Therapeutics has a beta of 2.08, suggesting that its share price is 108% more volatile than the broader market. Comparatively, Xilio Therapeutics has a beta of -0.12, suggesting that its share price is 112% less volatile than the broader market.

In the previous week, Xilio Therapeutics had 3 more articles in the media than Applied Therapeutics. MarketBeat recorded 3 mentions for Xilio Therapeutics and 0 mentions for Applied Therapeutics. Xilio Therapeutics' average media sentiment score of 0.71 beat Applied Therapeutics' score of 0.00 indicating that Xilio Therapeutics is being referred to more favorably in the news media.

Company Overall Sentiment
Applied Therapeutics Neutral
Xilio Therapeutics Positive

Applied Therapeutics has a net margin of 0.00% compared to Xilio Therapeutics' net margin of -58.52%. Xilio Therapeutics' return on equity of -151.42% beat Applied Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Applied TherapeuticsN/A -340.84% -175.00%
Xilio Therapeutics -58.52%-151.42%-27.61%

98.3% of Applied Therapeutics shares are held by institutional investors. Comparatively, 54.3% of Xilio Therapeutics shares are held by institutional investors. 1.6% of Applied Therapeutics shares are held by insiders. Comparatively, 7.5% of Xilio Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Applied Therapeutics presently has a consensus target price of $1.00, suggesting a potential upside of 870.87%. Xilio Therapeutics has a consensus target price of $28.00, suggesting a potential upside of 189.56%. Given Applied Therapeutics' higher possible upside, research analysts plainly believe Applied Therapeutics is more favorable than Xilio Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Applied Therapeutics
1 Sell rating(s)
2 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.67
Xilio Therapeutics
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
1 Strong Buy rating(s)
2.50

Xilio Therapeutics has higher revenue and earnings than Applied Therapeutics. Xilio Therapeutics is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Applied Therapeutics$1M15.86-$105.62M-$0.10N/A
Xilio Therapeutics$53.48M1.19-$35.04M-$3.55N/A

Summary

Xilio Therapeutics beats Applied Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Applied Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for APLT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

APLT vs. The Competition

MetricApplied TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$15.86M$3.64B$6.78B$12.58B
Dividend YieldN/A2.21%2.66%6.21%
P/E Ratio-1.0321.2327.3224.89
Price / Sales15.86336.45559.95116.34
Price / CashN/A62.1029.1436.96
Price / Book0.218.8111.076.57
Net Income-$105.62M$23.81M$3.57B$336.70M
7 Day PerformanceN/A3.60%2.49%3.24%
1 Month PerformanceN/A1.59%0.83%1.67%
1 Year Performance-66.89%69.67%36.80%31.94%

Applied Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
APLT
Applied Therapeutics
N/A$0.10
flat
$1.00
+870.9%
N/A$15.86M$1MN/A30
PMVP
PMV Pharmaceuticals
3.5015 of 5 stars
$1.15
-2.5%
$5.00
+334.8%
+20.6%$62.93MN/AN/A50
OKYO
OKYO Pharma
2.9484 of 5 stars
$1.54
-0.6%
$6.33
+311.3%
-38.0%$62.86MN/AN/A7
EXOZ
eXoZymes
0.9134 of 5 stars
$7.40
+3.6%
N/A-19.0%$60.54M$70KN/A29
INKT
MiNK Therapeutics
3.3655 of 5 stars
$11.31
-6.6%
$35.00
+209.5%
+70.6%$60.33MN/AN/A30

Related Companies and Tools


This page (NASDAQ:APLT) was last updated on 6/30/2026 by MarketBeat.com Staff.
From Our Partners